ZBIO vs IMCR โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
IMCR Captures Institutional Edge (3โ1 Pillars ยท 5โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immunocore Holdings plc American Depositary Shares (IMCR) driven by superior Valuation, Growth & Margin, Momentum & Technical while ZBIO counters with relative strength in Options & Structure. Fundamentally, ZBIO trades at N/M Forward P/E with -2747.5% operating margin (-100.0% YoY revenue) versus IMCR at 22.6x Forward P/E and -2.2% operating margin (-1.4% YoY). In options structure, ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro) against IMCR sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ZBIO | IMCR | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.9B | $1.5B | Larger Scale | ZBIO |
| Trailing P/E Ratio Valuation | N/M | 23.8x | Lower Multiple | IMCR |
| Forward P/E Ratio Valuation | N/M | 22.6x | Lower Multiple | IMCR |
| Revenue Growth (YoY) Growth | -100.0% | -1.4% | Higher Growth | IMCR |
| Operating Margin (TTM) Profitability | -2747.5% | -2.2% | Higher Margin | IMCR |
| Net Profit Margin Profitability | 0.0% | -7.5% | Higher Margin | ZBIO |
| Return on Equity (ROE) Capital Efficiency | -265.1% | -7.9% | Higher ROE | IMCR |
| 52-Week Range Position Momentum | 46% ($14โ$45) | 10% ($28โ$41) | Stronger Trend | ZBIO |
| Beta / 30D Volatility Risk Regime | 1.16ฮฒ ยท 59% Vol | 0.63ฮฒ ยท 59% Vol | Lower Realized Risk | Tie |
| Unified Institutional Score Composite Signal | 49.4 / 100 (HOLD) | 46.3 / 100 (HOLD) | Higher Composite | ZBIO |